Roger Reddel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5412029/publications.pdf

Version: 2024-02-01

196 papers 19,854 citations

76 h-index 134 g-index

206 all docs

206 docs citations

206 times ranked 17404 citing authors

#	Article	IF	CITATIONS
1	Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Medicine, 1997, 3, 1271-1274.	30.7	1,157
2	Alternative lengthening of telomeres: models, mechanisms and implications. Nature Reviews Genetics, 2010, 11, 319-330.	16.3	815
3	Telomere maintenance by recombination in human cells. Nature Genetics, 2000, 26, 447-450.	21.4	792
4	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	27.8	716
5	Protein Composition of Catalytically Active Human Telomerase from Immortal Cells. Science, 2007, 315, 1850-1853.	12.6	595
6	Alternative lengthening of telomeres in mammalian cells. Oncogene, 2002, 21, 598-610.	5.9	581
7	Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types. Human Molecular Genetics, 1997, 6, 2011-2019.	2.9	524
8	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
9	Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway. PLoS Genetics, 2012, 8, e1002772.	3.5	489
10	DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nature Biotechnology, 2009, 27, 1181-1185.	17.5	406
11	Check your cultures! A list of crossâ€contaminated or misidentified cell lines. International Journal of Cancer, 2010, 127, 1-8.	5.1	404
12	Alternative Lengthening of Telomeres Is Characterized by High Rates of Telomeric Exchange. Cancer Research, 2004, 64, 2324-2327.	0.9	283
13	Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet, The, 2003, 361, 836-838.	13.7	245
14	Coexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells. Molecular and Cellular Biology, 2001, 21, 3862-3875.	2.3	224
15	Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nature Structural and Molecular Biology, 2009, 16, 1244-1251.	8.2	220
16	Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. International Journal of Cancer, 2006, 118, 2973-2980.	5.1	214
17	Inactivation of Tumor Suppressor p53 by Mot-2, a hsp70 Family Member. Journal of Biological Chemistry, 1998, 273, 29586-29591.	3.4	207
18	Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Letters, 2010, 584, 3800-3811.	2.8	206

#	Article	IF	Citations
19	The role of senescence and immortalization in carcinogenesis. Carcinogenesis, 2000, 21, 477-484.	2.8	205
20	Telomere dynamics and telomerase activity in in vitro immortalised human cells. European Journal of Cancer, 1997, 33, 767-773.	2.8	203
21	A novel human cDNA highly homologous to the fish hormone stanniocalcin. Molecular and Cellular Endocrinology, 1995, 112, 241-247.	3.2	200
22	Human POT1 Facilitates Telomere Elongation by Telomerase. Current Biology, 2003, 13, 942-946.	3.9	195
23	The hTERTα Splice Variant is a Dominant Negative Inhibitor of Telomerase Activity. Neoplasia, 2000, 2, 426-432.	5.3	194
24	A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clinical Cancer Research, 2005, 11, 217-25.	7.0	191
25	The first molecular details of ALT in human tumor cells. Human Molecular Genetics, 2005, 14, R191-R196.	2.9	186
26	Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. European Journal of Cancer & Clinical Oncology, 1983, 19, 615-621.	0.7	181
27	The Telomere Lengthening Mechanism in Telomerase-Negative Immortal Human Cells Does Not Involve the Telomerase RNA Subunit. Human Molecular Genetics, 1997, 6, 921-926.	2.9	179
28	Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO Journal, 2009, 28, 799-809.	7.8	178
29	Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Reports, 2012, 13, 52-59.	4.5	178
30	Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nature Structural and Molecular Biology, 2015, 22, 875-880.	8.2	174
31	Alternative lengthening of telomeres, telomerase, and cancer. Cancer Letters, 2003, 194, 155-162.	7.2	172
32	Telomere maintenance mechanisms and cellular immortalization. Current Opinion in Genetics and Development, 1999, 9, 97-103.	3.3	165
33	Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation, 1988, 38, 60-66.	1.9	164
34	Hsp70 Family Member, mot-2/mthsp70/GRP75, Binds to the Cytoplasmic Sequestration Domain of the p53 Protein. Experimental Cell Research, 2002, 274, 246-253.	2.6	162
35	Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Science, 2008, 99, 1092-1099.	3.9	147
36	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. Cancer Research, 2013, 73, 1287-1297.	0.9	144

#	Article	IF	Citations
37	Suppression of Alternative Lengthening of Telomeres by Sp100-Mediated Sequestration of the MRE11/RAD50/NBS1 Complex. Molecular and Cellular Biology, 2005, 25, 2708-2721.	2.3	141
38	Mammalian stanniocalcins and cancer Endocrine-Related Cancer, 2003, 10, 359-373.	3.1	140
39	Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Research, 2009, 37, 1152-1159.	14.5	137
40	Telomere maintenance and cancer? look, no telomerase. Nature Reviews Cancer, 2002, 2, 879-884.	28.4	135
41	ATRX represses alternative lengthening of telomeres. Oncotarget, 2015, 6, 16543-16558.	1.8	135
42	Disruption of Telomere Maintenance by Depletion of the MRE11/RAD50/NBS1 Complex in Cells That Use Alternative Lengthening of Telomeres. Journal of Biological Chemistry, 2007, 282, 29314-29322.	3.4	133
43	Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. Journal of Cell Biology, 2012, 199, 893-906.	5.2	129
44	Cancer and Telomeresâ€"An ALTernative to Telomerase. Science, 2012, 336, 1388-1390.	12.6	127
45	BLM and SLX4 play opposing roles in recombinationâ€dependent replication at human telomeres. EMBO Journal, 2017, 36, 2907-2919.	7.8	127
46	The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT). Nature Communications, 2019, 10, 2252.	12.8	125
47	DNA Replication Licensing and Progenitor Numbers Are Increased by Progesterone in Normal Human Breast. Endocrinology, 2009, 150, 3318-3326.	2.8	122
48	Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells. Nature Genetics, 2002, 30, 301-305.	21.4	117
49	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. Cancer Research, 2006, 66, 8918-8924.	0.9	115
50	Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene, 2002, 21, 128-139.	5.9	112
51	Alternative lengthening of telomeres in normal mammalian somatic cells. Genes and Development, 2013, 27, 18-23.	5.9	111
52	Telomere uncapping and alternative lengthening of telomeres. Mechanisms of Ageing and Development, 2008, 129, 99-108.	4.6	108
53	Telomere Length Dynamics in Telomerase-Positive Immortal Human Cell Populations. Experimental Cell Research, 1998, 239, 370-378.	2.6	107
54	Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Research, 2002, 62, 1289-95.	0.9	107

#	Article	ΙF	Citations
55	Alternative Lengthening of Telomeres in Human Cells. Radiation Research, 2001, 155, 194-200.	1.5	104
56	Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. European Journal of Cancer & Clinical Oncology, 1984, 20, 1419-1424.	0.7	103
57	Identification of a second stanniocalcin cDNA in mouse and human: Stanniocalcin 2. Molecular and Cellular Endocrinology, 1998, 141, 95-99.	3.2	102
58	Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene, 2007, 26, 4635-4647.	5.9	102
59	NuRD–ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination. Nature Structural and Molecular Biology, 2014, 21, 760-770.	8.2	101
60	p16INK4a and the control of cellular proliferative life span. Carcinogenesis, 1999, 20, 921-926.	2.8	100
61	Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Oncogene, 1999, 18, 3383-3390.	5.9	100
62	Correction of the Copper Transport Defect of Menkes Patient Fibroblasts by Expression of the Menkes and Wilson ATPases. Journal of Biological Chemistry, 1998, 273, 31375-31380.	3.4	97
63	Inherited bone marrow failure associated with germline mutation of ACD, the gene encoding telomere protein TPP1. Blood, 2014, 124, 2767-2774.	1.4	97
64	STC1 expression is associated with tumor growth and metastasis in breast cancer. Clinical and Experimental Metastasis, 2015, 32, 15-27.	3.3	95
65	The C-Circle Assay for alternative-lengthening-of-telomeres activity. Methods, 2017, 114, 74-84.	3.8	95
66	Invasive and Metastatic Potential of a v-Ha-ras-Transformed Human Bronchial Epithelial Cell Line. Journal of the National Cancer Institute, 1989, 81, 587-594.	6.3	94
67	Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Experimental Cell Research, 2003, 286, 96-101.	2.6	93
68	Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. Nucleic Acids Research, 2014, 42, 1733-1746.	14.5	92
69	Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. European Journal of Cancer & Clinical Oncology, 1983, 19, 307-318.	0.7	90
70	Telomerase-Independent Telomere Length Maintenance in the Absence of Alternative Lengthening of Telomeres–Associated Promyelocytic Leukemia Bodies. Cancer Research, 2005, 65, 2722-2729.	0.9	90
71	Normal mammalian cells negatively regulate telomere length by telomere trimming. Human Molecular Genetics, 2011, 20, 4684-4692.	2.9	87
72	Malignant transformation of NIH3T3 cells by overexpression of mot-2 protei. Oncogene, 1998, 17, 907-911.	5.9	86

#	Article	IF	CITATIONS
73	The Murine Stanniocalcin 2 Gene Is a Negative Regulator of Postnatal Growth. Endocrinology, 2008, 149, 2403-2410.	2.8	82
74	Correlation between Complementation Group for Immortality and the Cellular Distribution of Mortalin. Experimental Cell Research, 1995, 216, 101-106.	2.6	81
75	Molecular cloning and characterization of mouse stanniocalcin cDNA. Molecular and Cellular Endocrinology, 1996, 124, 185-187.	3.2	80
76	p53 Localizes to the Centrosomes and Spindles of Mitotic Cells in the Embryonic Chick Epiblast, Human Cell Lines, and a Human Primary Culture: An Immunofluorescence Study. Experimental Cell Research, 2000, 256, 122-130.	2.6	79
77	DNA Damage Induces Alternative Lengthening of Telomeres (ALT)–Associated Promyelocytic Leukemia Bodies that Preferentially Associate with Linear Telomeric DNA. Cancer Research, 2007, 67, 7072-7077.	0.9	78
78	Alternative lengthening of telomeres: remodeling the telomere architecture. Frontiers in Oncology, 2013, 3, 27.	2.8	78
79	Concordant Epigenetic Silencing of Transforming Growth Factor-Î ² Signaling Pathway Genes Occurs Early in Breast Carcinogenesis. Cancer Research, 2007, 67, 11517-11527.	0.9	76
80	Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. Journal of Neuropathology and Experimental Neurology, 2010, 69, 729-736.	1.7	76
81	Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Research, 2013, 41, e34-e34.	14.5	75
82	Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Reports, 2017, 19, 2544-2556.	6.4	75
83	Strategies to enable large-scale proteomics for reproducible research. Nature Communications, 2020, 11, 3793.	12.8	75
84	hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. Nucleic Acids Research, 2005, 33, 486-496.	14.5	74
85	Telomere Maintenance Mechanisms in Cancer: Clinical Implications. Current Pharmaceutical Design, 2014, 20, 6361-6374.	1.9	74
86	Inactivation of p53 and life span extension of human diploid fibroblasts by mot-2. FEBS Letters, 2000, 474, 159-164.	2.8	73
87	Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochemical Journal, 2000, 350, 453-461.	3.7	72
88	Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma. Cancer Research, 2006, 66, 6473-6476.	0.9	72
89	Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral harvey <i>ras</i> . Molecular Carcinogenesis, 1988, 1, 151-160.	2.7	68
90	Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Human Molecular Genetics, 2009, 18, 3098-3109.	2.9	65

#	Article	IF	CITATIONS
91	Stanniocalcin-1 Inhibits Renal Ischemia/Reperfusion Injury via an AMP-Activated Protein Kinase-Dependent Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 364-378.	6.1	65
92	Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres. PLoS ONE, 2012, 7, e50062.	2.5	64
93	An N-terminal Region of Mot-2 Binds to p53 In Vitro. Neoplasia, 2001, 3, 110-114.	5.3	62
94	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. Clinical Cancer Research, 2008, 14, 4134-4140.	7.0	61
95	Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Human Molecular Genetics, 2009, 18, 1017-1027.	2.9	59
96	CARF Is a Novel Protein That Cooperates with Mouse p19 (Human p14) in Activating p53. Journal of Biological Chemistry, 2002, 277, 37765-37770.	3.4	58
97	The Murine Stanniocalcin 1 Gene Is Not Essential for Growth and Development. Molecular and Cellular Biology, 2005, 25, 10604-10610.	2.3	58
98	A sensitive direct human telomerase activity assay. Nature Methods, 2008, 5, 355-360.	19.0	58
99	Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Molecular and Cellular Endocrinology, 1996, 124, 17-23.	3.2	57
100	A reassessment of the telomere hypothesis of senescence. BioEssays, 1999, 20, 977-984.	2.5	57
101	Assignment of SV40-Immortalized Cells to More Than One Complementation Group for Immortalization. Experimental Cell Research, 1993, 205, 337-344.	2.6	56
102	â^†133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling. Nature Communications, 2018, 9, 254.	12.8	55
103	The role of telomere trimming in normal telomere length dynamics. Cell Cycle, 2012, 11, 1309-1315.	2.6	53
104	Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene, 2009, 28, 1982-1992.	5.9	52
105	Senescence: an antiviral defense that is tumor suppressive?. Carcinogenesis, 2010, 31, 19-26.	2.8	52
106	Pan-cancer proteomic map of 949 human cell lines. Cancer Cell, 2022, 40, 835-849.e8.	16.8	52
107	Alterations in the p16INK4a and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene, 2004, 23, 3116-3121.	5.9	51
108	Differential display of mRNA. Molecular Biotechnology, 1998, 10, 155-165.	2.4	48

#	Article	IF	CITATIONS
109	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	2.5	48
110	Sv40-induced immortalization andras-transformation of human bronchial epithelial cells. International Journal of Cancer, 1995, 61, 199-205.	5.1	45
111	Genes Involved in the Control of Cellular Proliferative Potentiala. Annals of the New York Academy of Sciences, 1998, 854, 8-19.	3.8	44
112	Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. Journal of Cell Biology, 2009, 185, 797-810.	5.2	43
113	Comparative analysis of whole genome sequencing-based telomere length measurement techniques. Methods, 2017, 114, 4-15.	3.8	43
114	MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. Nucleic Acids Research, 2011, 39, 8078-8091.	14.5	42
115	Pex19p Dampens the p19ARF-p53-p21WAF1 Tumor Suppressor Pathway*. Journal of Biological Chemistry, 2001, 276, 18649-18652.	3.4	41
116	Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences. Cell Death and Disease, 2017, 8, e2755-e2755.	6.3	41
117	Constructing immortalized human cell lines. Current Opinion in Biotechnology, 1999, 10, 465-469.	6.6	40
118	Telomere sequence content can be used to determine ALT activity in tumours. Nucleic Acids Research, 2018, 46, 4903-4918.	14.5	40
119	Alternative lengthening of telomeres: dangerous road less travelled. Lancet, The, 2003, 361, 1840-1841.	13.7	39
120	PAX8 Regulates Telomerase Reverse Transcriptase and Telomerase RNA Component in Glioma. Cancer Research, 2008, 68, 5724-5732.	0.9	39
121	Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics and Chromatin, 2018, 11 , 24 .	3.9	38
122	Role of POT1 in Human Cancer. Cancers, 2020, 12, 2739.	3.7	36
123	A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase. PLoS Genetics, 2015, 11, e1005286.	3.5	35
124	Inhibition of SV40 large T antigen induced apoptosis by small T antigen. Oncogene, 1999, 18, 5598-5603.	5.9	32
125	Human Stanniocalcin (STC): Genomic Structure, Chromosomal Localization, and the Presence of CAG Trinucleotide Repeats. Genomics, 1998, 47, 393-398.	2.9	31
126	Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3062-71.	7.1	31

#	Article	IF	Citations
127	Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Experimental Cell Research, 1992, 203, 297-304.	2.6	29
128	A Major Functional Difference between the Mouse and Human ARF Tumor Suppressor Proteins. Journal of Biological Chemistry, 2002, 277, 36665-36670.	3.4	29
129	A Study of <i>TP53</i> RNA Splicing Illustrates Pitfalls of RNA-seq Methodology. Cancer Research, 2016, 76, 7151-7159.	0.9	29
130	Cell cycle effects of iron depletion on T-47D human breast cancer cells. Experimental Cell Research, 1985, 161, 277-284.	2.6	28
131	HPV-16 E6 and E7 Genes, like SV40 Early Region Genes, Are Insufficient for Immortalization of Human Mesothelial and Bronchial Epithelial Cells. Experimental Cell Research, 1994, 213, 418-427.	2.6	28
132	Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience, 2013, 229, 49-54.	2.3	28
133	DNA methylation mediated up-regulation of <i>TERRA < /i> non-coding RNA is coincident with elongated telomeres in the human placenta. Molecular Human Reproduction, 2016, 22, 791-799.</i>	2.8	28
134	Normal telomere maintenance in immortal ataxia telangiectasia cell lines. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 379, 177-184.	1.0	27
135	Identification of a 55-kDa Ezrin-Related Protein That Induces Cytoskeletal Changes and Localizes to the Nucleolus. Experimental Cell Research, 1999, 250, 51-61.	2.6	27
136	Telomere Biology: A New Player in the End Zone. Current Biology, 2004, 14, R901-R902.	3.9	27
137	Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome. Human Molecular Genetics, 2005, 14, 1785-1794.	2.9	27
138	Extreme Telomere Length Dimorphism in the Tasmanian Devil and Related Marsupials Suggests Parental Control of Telomere Length. PLoS ONE, 2012, 7, e46195.	2.5	27
139	Genetic Differences between the Pancytosolic and Perinuclear Forms of Murine Mortalin. Experimental Cell Research, 1996, 226, 381-386.	2.6	26
140	Enhanced isolation of fibroblasts from human skin explants. BioTechniques, 2012, 53, 239-244.	1.8	26
141	Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis. Clinical Epigenetics, 2015, 7, 52.	4.1	26
142	Structurally and Functionally Distinct Mouse Hsp70 Family Members Mot-1 and Mot-2 Proteins are Encoded by Two Alleles. DNA Research, 2000, 7, 229-231.	3.4	25
143	Molecular characterization of collaborator of ARF (CARF) as a DNA damage response and cell cycle checkpoint regulatory protein. Experimental Cell Research, 2014, 322, 324-334.	2.6	25
144	Addressing the Challenges of Highâ€Throughput Cancer Tissue Proteomics for Clinical Application: ProCan. Proteomics, 2019, 19, e1900109.	2.2	25

#	Article	IF	Citations
145	HP1-Mediated Formation of Alternative Lengthening of Telomeres-Associated PML Bodies Requires HIRA but Not ASF1a. PLoS ONE, 2011, 6, e17036.	2.5	25
146	Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochemical Journal, 2000, 350, 453.	3.7	24
147	Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX. Nature Communications, 2021, 12, 1552.	12.8	24
148	Downregulation of metallothionein-IIA expression occurs at immortalization. Oncogene, 1999, 18, 897-903.	5.9	23
149	Functional dissection of breast cancer risk-associated <i>TERT</i> promoter variants. Oncotarget, 2017, 8, 67203-67217.	1.8	21
150	Telomerase activity in pleural malignant mesotheliomas. Lung Cancer, 2011, 73, 283-288.	2.0	20
151	Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency. Molecular Therapy - Nucleic Acids, 2017, 6, 1-14.	5.1	20
152	Targeted Therapy of <i>TERT</i> -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. Clinical Cancer Research, 2021, 27, 1438-1451.	7.0	20
153	Enhancement of the invasive ability of a transformed human bronchial epithelial cell line by 12-O-tetra-decanoyl-phorbol-13-acetate and diacylglycerol. Carcinogenesis, 1989, 10, 2335-2338.	2.8	19
154	Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency. Journal of Cell Science, 2019, 132, .	2.0	19
155	Expression and localisation of stanniocalcin 1 in rat bladder, kidney and ovary. Electrophoresis, 1999, 20, 2071-2076.	2.4	18
156	Amplification of Telomerase Reverse Transcriptase Gene in Human Mammary Epithelial Cells with Limiting Telomerase RNA Expression Levels. Cancer Research, 2008, 68, 3115-3123.	0.9	18
157	Fibroblast-Derived STC-1 Modulates Tumor-Associated Macrophages and Lung Adenocarcinoma Development. Cell Reports, 2020, 31, 107802.	6.4	18
158	Transcriptional Inactivation of p53 by Deletions and Single Amino Acid Changes in Mouse mot-1 Protein. Biochemical and Biophysical Research Communications, 2000, 279, 602-606.	2.1	16
159	Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas. Oncogene, 2001, 20, 2600-2605.	5.9	16
160	Regulation of the interferon-gamma (IFN- \hat{l}^3) pathway by p63 and \hat{l}^* 133p53 isoform in different breast cancer subtypes. Oncotarget, 2018, 9, 29146-29161.	1.8	16
161	Chromosomal changes and progressive tumorigenesis of human bronchial epithelial cell lines. Cancer Genetics and Cytogenetics, 1996, 92, 99-110.	1.0	15
162	MatCol: a tool to measure fluorescence signal colocalisation in biological systems. Scientific Reports, 2017, 7, 8879.	3.3	14

#	Article	IF	CITATIONS
163	Telomeres in the Haemopoietic System. Novartis Foundation Symposium, 1997, 211, 209-226.	1.1	14
164	Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. Oncogene, 2009, 28, 2678-2689.	5.9	13
165	Intronic TP53 Polymorphisms Are Associated with Increased Δ133TP53 Transcript, Immune Infiltration and Cancer Risk. Cancers, 2020, 12, 2472.	3.7	13
166	A human bronchial epithelial cell strain with unusualin vitro growth potential which undergoes neoplastic transformation after SV40 T antigen gene transfection. International Journal of Cancer, 1991, 48, 764-773.	5.1	11
167	Effects of Simian Virus 40 T-Antigens on Normal Human Mammary Epithelial Cells Reveal Evidence for Spontaneous Alterations in Addition to Loss of p16INK4a Expression. Experimental Cell Research, 2001, 265, 125-134.	2.6	11
168	The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity. Cancers, 2021, 13, 5369.	3.7	10
169	Identification of a Novel Human Mitochondrial D-Loop RNA Species Which Exhibits Upregulated Expression Following Cellular Immortalization. Biochemical and Biophysical Research Communications, 2000, 276, 439-446.	2.1	9
170	Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21WAF1/CIP1. Journal of Cell Science, 2009, 122, 2989-2995.	2.0	9
171	An alternative lifestyle for immortalized oral keratinocytes. Journal of Clinical Investigation, 2001, 108, 665-667.	8.2	9
172	N-Desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in Vitro. European Journal of Cancer & Clinical Oncology, 1983, 19, 1179-1181.	0.7	8
173	Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos. Carcinogenesis, 1992, 13, 1359-1363.	2.8	8
174	Immortalization of human fibroblasts by liposome-mediated transfer of SV40 early region genes. Cytotechnology, 1995, 17, 75-81.	0.7	8
175	An effective elimination of false positives isolated from differential display of mRNAs. Molecular Biotechnology, 1996, 6, 213-217.	2.4	8
176	Is cell culture a risky business? Risk analysis based on scientist survey data. International Journal of Cancer, 2016, 138, 664-670.	5.1	7
177	Reassessment of immortalization complementation group D. Experimental Gerontology, 1997, 32, 663-670.	2.8	5
178	Cloning and Characterization of a Novel Gene, striamin, That Interacts with the Tumor Suppressor Protein p53. Journal of Biological Chemistry, 1999, 274, 14948-14955.	3.4	5
179	Oncogenes and Tumor Suppressor Genes Involved in Human Lung Carcinogenesis., 1990, 53, 363-379.		5
180	qmotif: determination of telomere content from whole-genome sequence data. Bioinformatics Advances, 2022, 2, .	2.4	5

#	Article	IF	Citations
181	A SUMO ligase for ALT. Nature Structural and Molecular Biology, 2007, 14, 570-571.	8.2	4
182	Functional characterization of miR-708 microRNA in telomerase positive and negative human cancer cells. Scientific Reports, 2021, 11, 17052.	3 . 3	4
183	Alternative lengthening of telomeres in mammalian cells. , 0, .		4
184	Stanniocalcin2, but Not Stanniocalcin1, Responds to Hypoxia in a HIF1-Dependent Manner in the Retina. Frontiers in Neuroscience, 0, 16 , .	2.8	3
185	Immortalization techniques. Cytotechnology, 1995, 17, 65-66.	0.7	1
186	Molecular Markers and Long-term Survivors of Glioblastoma Multiforme. Cancer Journal (Sudbury,) Tj ETQq0 0 0	rgBT/Ove	erlock 10 Tf 50
187	Chimerism and Tolerance in a Recipient of a Deceased-Donor Liver Transplant. New England Journal of Medicine, 2008, 358, 2075-2075.	27.0	1
188	A novel cause of DKC1 â€related bone marrow failure: Partial deletion of the 3′ untranslated region. EJHaem, 2021, 2, 157-166.	1.0	1
189	Alternative Lengthening of Telomeres in Human Cells. , 2009, , 127-148.		1
190	Genetic changes during immortalization of human cells. Radiation Oncology Investigations, 1995, 3, 299-306.	0.9	0
191	End Products of Telomere Research. Cell Stem Cell, 2020, 26, 804-805.	11.1	O
192	Telomeres and Cellular Aging. , 2003, , 171-205.		0
193	Senescence and Immortalization. , 2011, , 3371-3373.		O
194	Senescence and Immortalization. , 2015, , 4174-4177.		0
195	Abstract A22: Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency. , 2017, , .		O
196	Senescence and Immortalization. , 0, , 2697-2699.		0